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Introduction
Thymomas are the most common primary anterior mediastinal tumor and account for 15% to 20% of 
all mediastinal masses.(1, 3, 4) Although the majority of thymomas appear histologically benign, some 
may behave like invasive epithelial malignancies, invading local structures or metastasizing to distant 
organs.(2) However, extrathoracic direct invasion or distant metastasis are extremely rare and only a 
few cases have been reported previously. Even fewer cases of gastrointestinal tract invasion of thymo-
mas have been documented in the English literature.(5, 6) This is the ﬁ  rst clinical report of mediastinal 
thymic carcinoma metastatic to proximal small bowel.
Case Report
A 59 year old African American man with a 75 pack-year tobacco history presented with intermittent 
nocturnal anterior chest and non-productive cough. A chest x-ray showed a density adjacent to the 
aortic arch (Fig. 1). Chest CT revealed an 8 × 2.3 cm anterior mediastinal mass located superiorly which 
extended from the inner margin of the sternum along the aortic arch and encased the left subclavian 
and left common carotid arteries (Fig. 2).
He underwent mediastinoscopy with partial thoracotomy (Chamberlain procedure) and biopsy which 
showed poorly differentiated thymic carcinoma (Fig. 3) with immunohistochemistry positive for AE1/
AE3, CD5, and vimentin (Fig. 4). PET scan showed the mediastinal mass with an SUV of 10. There 
was also uptake with SUV of 8.5 in a region close to the proximal intestine (Fig. 5). Because the PET 
suggested proximal bowel involvement, a colonoscope was used to visualize the proximal small bowel. 
This revealed a large fungating and ulcerated mass in the 4th (horizontal) part of the duodenum, about 
3 cm in diameter (Fig. 6). EUS showed an ulcerated intramural lesion, involving deep mucosal layer, 
submucosa, muscularis propria and serosal (Fig. 7). Three malignant-appearing, round, hypoechoic 
lymph nodes with well-deﬁ  ned margins, measuring from 10 to 15 mm were visualized in the peritumoral 
region. The duodenal biopsy showed an ulcerated duodenal mucosa with an inﬁ  ltrating epithelial neo-
plasm, composed of large polygonal cells, with abundant cytoplasm (Fig. 8). Only occasional intratu-
moral lymphocytes were present. The tumor did not exhibit any particular organoid or glandular growth 
pattern, and there was no tumor necrosis. A battery of immunostains was performed, including AE1/3, 
vimentin, CD3, CD20, CD10, S-100, monoclonal CEA, TTF, CDx-2, Ki-67, calretinin, and c-kit. The 
immunostains for AE1/3, mCEA, CK19, CK20 were strongly positive in tumor cells. CD10 was only 
focally weakly positive. All the other immunostains were negative.
The patient’s case was discussed in thoracic multi-disciplinary tumor board and the decision was 
made to treat with chemotherapy and radiation therapy. Radiation was added in this patient with meta-
static disease for palliation as he had signiﬁ  cant chest and left shoulder pain and also dyspnea on exer-
tion. Given his age and no other signiﬁ  cant medical co-morbid illnesses, we felt that he would tolerate 
concurrent treatment. The patient received 3 cycles of chemotherapy with cisplatinum and etoposide, 
both of which are reported to be active in thymic carcinoma.(18) Radiation was started with the ﬁ  rst 
cycle for 15 fractions to a total dose of 4500 cGy. The targets were the primary 8 cm mediastinal thymic 478
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Figure 1. Chest X-ray showing superior mediastinal mass.
Figure 2. Chest CT demonstrating mass with involvement of aortic 
arch.
Figure 3. Hematoxylin-Eosin stain of primary tumor (40x).
Figure 4. Immunohistochemistry staining with cytokeratine AE1/AE3.
carcinoma and the chest wall lesion located anterior 
to the distal sternum. The radiation was delivered 
via parallel opposed antero-posterior (AP) and 
postero-anterior (PA) beams with 6 and 18 
megavoltage (MV) photons respectively, to a dose 
of 2700 cGy. Additional dose of 1800 cGy was 
delivered to the primary mass via off-spinal-cord 
oblique ﬁ  elds with 6 MV photons. The chest wall 
lesion located anterior to the distal sternum was 
treated with 9MEV electrons to additional dose of 
1800 cGy; thus, bringing the total dose to 4500 cGy. 
He did achieve signiﬁ  cant pain relief at the end of 
his radiation course. His chemotherapy course was 
complicated by pulmonary embolism and febrile 
neutropenia. He had partial radiologic response to 
chemotherapy/radiation with decrease of his 
mediastinal mass to 6.6 × 2.8 cm. He felt very 
deconditioned with chemotherapy and declined 
further treatment after 3 cycles electing best sup-
portive care.
Discussion
The incidence of thymoma is 0.15 cases per 
100,000 based upon data from the National Cancer 
Institute Surveillance, Epidemiology, and End 
Results (SEER) program.(11) Most patients are 
between 40 and 60 years of age, and there is slight 
male predominance. Up to one-half of thymomas 
may be found as an incidentally detected radio-
graphic abnormality in an asymptomatic patient. 
In contrast, most patients with thymic carcinoma 
present with clinical symptoms, including cough, 
chest pain, phrenic nerve palsy, or superior vena 
cava syndrome.(12)479
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Although all thymomas are derived from the 
epithelial cells of the thymus, they represent a 
diverse group of tumors with varied histologic 
ﬁ  ndings and biologic behavior. Histological sub-
types include predominantly lymphocytic, pre-
dominantly epithelial, mixed lymphoepithelial, or 
spindle cell thymomas. The epithelial neoplastic 
cell usually grows slowly and lacks cytologic 
characteristics of malignancy. In contrast, 
thymic carcinomas, which account for less than 
1 percent of thymic malignancies, have overtly 
malignant cytologic characteristics (e.g. anaplasia, 
cellular atypia, and increased proliferative activity) 
and capsular invasion.(2, 12)
Like thymoma, thymic carcinoma is most com-
monly located in the anterosuperior mediastinum. 
Approximately 80% of these patients have evi-
dence of invasion of contiguous mediastinal 
Figure 6. Endoscopic photograph of ulcerated mass in distal 
duodenum.
Figure 5. PET-CT demonstrates uptake in mediastinal mass, and two foci close to proximal small intestine.
Figure 7. Endoscopic ultrasound of duodenal mass.480
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structures, and 40% have radiologically apparent 
lymphadenopathy.(13) As with thymomas, local 
metastases often involve the pleura and mediasti-
nal nodes, and sometimes, cervical and axillary 
lymph nodes, while distant metastases to the lungs, 
liver, brain and bone are rarely observed.(4, 7, 9) 
In addition renal and splenic metastasis have also 
been reported.(5, 6, 8)
Gastrointestinal tract invasion of thymomas is 
extremely uncommon. Brown et al. described a case 
of malignant thymoma with retroperitoneal exten-
sion below the diaphragm and invasion into the 
posterior wall of the stomach.(5) Fujikawa et al., 
reported a case of malignant thymoma that recurred 
three times during an 8-year period and invaded 
directly into the peritoneal cavity, involving the 
stomach, and transverse colon.(3) Bott-Kothari 
et al. reported a case of locally invasive mediastinal 
thymoma, which was initially treated with surgery 
and radiation therapy; 5 1/2 years later the patient 
was found to have a large mass in the abdomen and 
pelvis, involving the mesentery of the small intestine 
and a metastatic implant on the right ovary.(10)
Our case report is the ﬁ  rst clinical case report 
of thymic carcinoma with distant metastatic disease 
involving small bowel at the time of diagnosis. 
Microscopic examination of the distal duodenal 
mass revealed the features of invasive poorly dif-
ferentiated epithelial malignancy, the same subtype 
that was seen on the original mediastinal tumor 
biopsy. It has been reported that epithelial type 
thymomas are three times more likely to metasta-
size than as other types of thymoma.(9)
Non-invasive thymoma carries a generally good 
prognosis with 80% five-year survival rate. 
In contrast, the ﬁ  ve-year survival rate of patients 
with primary thymic carcinoma varies from 34 to 
65 percent(15) and was reported to be 35 percent 
at 10 years in one series.(16) Multimodality treat-
ment with induction chemotherapy, surgery, and 
postoperative radiotherapy may offer improved 
survival in patients with unresectable malignant 
thymomas.(17)
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Figure 8. Biopsy of duodenal mass; immunohistochemistry positive 
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